{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-081286","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.453319+00:00","generated_at":"2026-06-10T02:38:15.848901+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Jasper Therapeutics updates corporate presentation as of October 2023; no specific new data disclosed.","bullets":["Furnished updated corporate presentation under Regulation FD; presentation dated October 2023.","Presentation cover slide states Briquilimab is investigational and not approved for any indication.","No financial, clinical, or operational metrics from the presentation are included in the filing.","Company disclaims obligation to update the presentation material in the future."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-081286","json":"https://secwatch.observer/filing/0001213900-23-081286.json","markdown":"https://secwatch.observer/filing/0001213900-23-081286.md","text":"https://secwatch.observer/filing/0001213900-23-081286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023081286/0001213900-23-081286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023081286/ea186520-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:38:15.848901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}